Recurrent Disease Clinical Trial
Official title:
Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts
The efficacy of traditional therapeutic approaches for aneurysmal bone cysts (ABC), such as surgery, embolization, sclerotherapy and radiotherapy, are often compromised for lesions in axial skeletons and adolescents complicated with pathological fracture. Therefore, denosumab, a new drug that has been successfully used in giant cell tumor of bone but has seldom used in ABC, was used to treat ABC in this trial.
Patients with primary ABC treated with perioperative denosumab in the Musculoskeletal Tumor Center of Peking University People's Hospital between January 2014 and December 2016 will be reported in this trial.Approved by the Ethics Committee of Peking University People's Hospital and with the full informed consent from the patients or their families, all patients received surgery and treatment with denosumab perioperatively. Denosumab 120 mg was given subcutaneously (abdomen wall or upper arms) every 4 weeks (Q4W), with a loading dose on both Day 8 and Day 15 of the first cycle. Meanwhile, all patients were suggested to take 800mg oral calcium supplement every day and avoid any dental or oral surgery (tooth extraction, tooth filling, etc.). Patients were followed once a month since the date of surgery. On follow-up visits, patient-reported adverse reactions, X-ray image of jawbone, serum calcium, alkaline phosphatase, renal and hepatic function, hemoglobin, white blood cell, and platelet count were collected, and histological examinations, radiological examinations (such as X-ray, computed tomography (CT), magnetic resonance image (MRI) and positron emission tomography-computed tomography (PET-CT) and postoperative functional status evaluations by MSTS(Musculoskeletal tumor society) score were conducted. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02204761 -
Proton Beam Re-Irradiation in Thoracic Cancers
|
N/A | |
Completed |
NCT01445080 -
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
|
Phase 1/Phase 2 | |
Terminated |
NCT03525392 -
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
|
Phase 1 | |
Completed |
NCT01794845 -
Phase II Trial Using Erbitux+ Taxotere With Low Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
|
Phase 2 | |
Completed |
NCT02210858 -
Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT05432518 -
Pilot Trial for Treatment of Recurrent Glioblastoma
|
Early Phase 1 | |
Completed |
NCT00351975 -
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
|
Phase 1 | |
Completed |
NCT03060096 -
Stepped-Care Telehealth for Distress in Cancer Survivors
|
N/A | |
Not yet recruiting |
NCT03591666 -
A Study of Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas
|
Phase 2 | |
Completed |
NCT00036738 -
Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib
|
Phase 2 | |
Recruiting |
NCT05260671 -
Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN
|
Phase 2 | |
Completed |
NCT01737450 -
Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive
|
Phase 2 | |
Recruiting |
NCT06088719 -
Safety of Omitting Axillary Surgery in Breast Cancer Patients With Isolated Chest Wall Recurrence
|
||
Terminated |
NCT00408252 -
Efficacy of SU 011248 in Head And Neck Carcinoma
|
Phase 2 | |
Terminated |
NCT02488512 -
Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas
|
Phase 2 | |
Recruiting |
NCT02747732 -
Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL
|
Phase 2 | |
Completed |
NCT00383474 -
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase
|
Phase 1 | |
Completed |
NCT00003145 -
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia
|
Phase 2 | |
Recruiting |
NCT06014619 -
Complications and Recurrences After Mohs Micrographic Surgery and Slow Mohs
|
||
Active, not recruiting |
NCT03792256 -
Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
|
Phase 1 |